Voyager presents positive GLP tox data for tau gene therapy VY1706; plans H2 2026 dosing

Voyager Therapeutics, Inc.

GLP toxicology data for VY1706 showed favorable tolerability in NHPs with no adverse CNS or peripheral findings up to 5x10^13 vg/kg.
Single IV dose achieved up to 75% lowering of MAPT mRNA and tau protein in key AD brain regions through six months.
ALPL brain vasculature receptor mediated VY1706 blood-brain barrier transport, supporting cross-species translatability.
IND clearance received June 2026; multi-site open-label dose-escalation trial to begin dosing in H2 2026.
Data presented at Alzheimer's Association International Conference on July 13, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.